VGX 3100

Drug Profile

VGX 3100

Alternative Names: Human papillomavirus vaccine-VGX Pharmaceuticals; VGX-3100

Latest Information Update: 24 Feb 2016

Price : $50

At a glance

  • Originator University of Pennsylvania
  • Developer Inovio Pharmaceuticals
  • Class Cancer vaccines; DNA vaccines; Papillomavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cervical intraepithelial neoplasia; Human papillomavirus infections
  • Clinical Phase Unknown Head and neck cancer

Most Recent Events

  • 17 Sep 2015 Updated efficacy data from a phase II trial in Cervical intraepithelial neoplasia released by Inovio Pharmaceuticals
  • 17 Sep 2015 Inovio plans a phase III trial for Cervical intraepithelial neoplasia
  • 30 Jun 2015 VGX 3100 is still in phase II trials for Cervical intraepithelial neoplasia and Human papillomavirus infections in USA, Australia, Canada, Estonia, Georgia, India, Puerto Rico, South Africa and South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top